CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John...
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
September 26, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will...
CervoMed to Participate in Upcoming Investor Conferences
August 27, 2024 08:30 ET
|
CervoMed Inc.
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
August 22, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent...
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 12, 2024 08:00 ET
|
CervoMed Inc.
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December...
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
July 30, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s...
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
July 29, 2024 08:00 ET
|
CervoMed Inc.
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase...
CervoMed to Participate in the Emerging Growth Conference
July 17, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s...
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
July 11, 2024 08:51 ET
|
CervoMed Inc.
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE) --...
CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
June 24, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected...